Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence

被引：0
|
作者：
Davide Campana
Gabriele Capurso
Stefano Partelli
Francesca Nori
Francesco Panzuto
Domenico Tamburrino
Giulia Cacciari
Gianfranco Delle Fave
Massimo Falconi
Paola Tomassetti
机构：
[1] University of Bologna,Department of Medical and Surgical Sciences, S. Orsola
[2] “Sapienza” University of Rome,Malpighi Hospital
[3] Sacro Cuore Don Calabria Hospital,Digestive and Liver Disease Unit
[4] University of Verona,Department of Surgery
[5] Università Politecnica delle Marche,Department of Surgery
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2013年 / 40卷
关键词：
Lu-DOTATATE; Y-DOTATOC; Neuroendocrine tumours; Radiotherapy; Somatostatin receptors; Therapeutic chemoembolization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1197 / 1205
页数：8
相关论文
共 43 条
  • [21] Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
    Sorbye, H.
    Meyer, L. S.
    Mordal, K. E.
    Myhre, S.
    Thiis-Evensen, E.
    NEUROENDOCRINOLOGY, 2020, 110 : 106 - 106
  • [22] Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
    Halfdan Sorbye
    Liv Sylvi Meyer
    Kjersti Elisabeth Mordal
    Simen Myhre
    Espen Thiis-Evensen
    Health and Quality of Life Outcomes, 18
  • [23] Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
    Sorbye, Halfdan
    Meyer, Liv Sylvi
    Mordal, Kjersti Elisabeth
    Myhre, Simen
    Thiis-Evensen, Espen
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [24] The new radiolabelled somatostatin analogue 90Yttrium-dota-octreotate for the treatment of metastatic neuroendocrine tumors: Initial results and tolerability in a series of 47 patients
    Toumpanakis, C.
    Quigley, A.
    Srirajaskanthan, R.
    Karpathakis, A.
    Krepska, A.
    Davidson, A.
    Meyer, T.
    Buscombe, J.
    Caplin, M. E.
    GUT, 2007, 56 : A42 - A43
  • [25] Dynamic changes of SUVs in 68Ga-somatostatin analogue PET/CT in response to PRRT as a predictive factor in patients with neuroendocrine tumours
    Opalinska, M.
    Sowa-Staszczak, A.
    Kania-Kuc, A.
    Al Maraih, I.
    Morawiec-Slawek, K.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S468 - S468
  • [26] Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Kwekkeboom, DJ
    Bakker, WH
    Kam, BL
    Teunissen, JJM
    Kooij, PPM
    Herder, WW
    Feelders, RA
    Eijck, CHJ
    Jong, M
    Srinivasan, A
    Erion, JL
    Krenning, EP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) : 417 - 422
  • [27] Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    D. J. Kwekkeboom
    W. H. Bakker
    B. L. Kam
    J. J. M. Teunissen
    P. P. M. Kooij
    W. W. de Herder
    R. A. Feelders
    C. H. J. van Eijck
    M. de Jong
    A. Srinivasan
    J. L. Erion
    E. P. Krenning
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 417 - 422
  • [28] The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment
    Shi, W
    Buchanan, KD
    Johnston, CF
    Larkin, C
    Ong, YL
    Ferguson, R
    Laird, J
    CLINICAL ENDOCRINOLOGY, 1998, 48 (03) : 303 - 309
  • [29] Use of Multiple Sources of Electronic Healthcare Record (EHR) Drug Data to Study Somatostatin Analogue (SSA) Dosing for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Treatment
    Jalbert, Jessica J.
    Meng, Jie
    Brais, Lauren K.
    Dutton, Trevor
    Pulgar, Sonia J.
    Berthon, Anthony
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    Casciano, Roman
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 122 - 122
  • [30] A phase I/II study of a new radiolabeled somatostatin analogue 90Yttrium-Tyr3-DOTA-octreotate for the treatment of metastatic neuroendocrine tumours
    Toumpanakis, Christos
    Shah, Tahir
    Chong, Nick
    Davies, Neil
    Buscombe, John
    Caplin, Martyn E.
    GASTROENTEROLOGY, 2006, 130 (04) : A583 - A583
12345